Evotec is a holding company engaged as a drug discovery solutions company providing drug discovery capabilities to pharmaceutical and biotechnology companies as well as to academic institutions. These drug discovery solutions are provided in form of fee-for service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Co. is primarily involved in the areas of neuroscience, pain, metabolic diseases, oncology and inflammation. Co. provides its drug discovery activities under the banners of EVT Execute, EVT Integrate and EVT Innovate. Co.'s operations are divided into two segments: EVT Execute and EVT Innovate.
  • Ticker566480
  • ISINDE0005664809
  • SectorPharmaceuticals & Biotechnology
  • CountryGermany


Thomas J. Schiessle

Sehr guter Start ins Gj. 2019 macht Hoffnung auf mehr

Mit einem sehr guten und von uns erwarteten Q1/19 startete das Gj. 2019, das auch im weiteren Verlauf kräftiges Wachstum verspricht. Die Kundenbasis wird breiter, die Nachfrage im Basisgeschäft ist und bleibt hoch (INDiGO, iPSC), ergänzt um mögliche Meilensteine (wichtige Studienstarts). Das Q1/19 startete mit einem Umsatzplus von 27 % ggü. Q1/18. Gutes Basisgeschäft; mehr Meilensteine und hohe F+E-Steuergutschriften kamen dazu.

Expert Corporate Governance Service (ECGS)

Evotec - AGM 19 June 2019

General: Evotec was founded 1993 in Hamburg, Today, the Company is a publicly listed drug discovery and development company that operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists. As of 3 April 2019, Novo Holdings A/S held between 10% and 15%, ROI Verwaltungsgesellschaft mbH/Roland Oetker, and The Goldman Sachs Group, Inc. each held between 5% and 10%, and Allianz Global Investors GmbH and DWS Investment GmbH each held between 3% and 5% of the Company's shares. Note th...

Dave Nicoski ...
  • Ross LaDuke

Int'l Insights: Developed Markets Leadership Chart Book

Europe in focus The U.S. dollar continues to grind marginally higher, and EM equities have suffered as a result. Meanwhile, RS for the MSCI EAFE index is bottoming when compared to the MSCI EM index, largely due to outperformance in Europe. With developed int'l markets beginning to outperform emerging markets, we recommend adding exposure to the developed int'l space. Below we highlight attractive and actionable themes within developed int'l: • Europe & Japan: Though this is an all-encompassing bottoms-up chart book for developed ex-U.S., make no mistake, the vast majority of today's buy rec...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch